Auburn became the latest program to join the coaching carousel and we take a look at some potential candidates.

AAVantgarde Bio has announced the successful closing of a $141 million (€122 million) Series B financing round that was co-led by a new lead, Schroders Capital, as well as existing investors Atlas ...

Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHLPreclinical data demonstrated that combining ...

Innovation is never easy. It requires the audacity to create a new path, one where we will encounter novel obstacles that demand both resourcefulness and bold imagination. But when we stand together, ...

Advanced CGTs are expanding to larger patient populations, requiring strategic distribution approaches centered on patient needs. Effective channel strategies, broadening access, and reducing ...

AMT-130, aimed at treating Huntington’s disease (HD). This article will delve into the recent feedback from the U.S. Food and Drug Administration (FDA), the implications for the therapy's regulatory ...

From heartbreaking losses to iconic wins, the Arizona Cardinals have built a long history on Monday Night Football.

Benitec Biopharma Inc. (NASDAQ:BNTC) shares soared 20% on Monday after the biotech company announced positive interim results ...

Uniqure stock crashed Monday on "confusing" and "unexpected" feedback from the FDA for its Huntington's disease gene therapy.

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.